Cerivastatin gender effect: Sub-analyses of results from a multinational, randomised, double-blind study

We previously reported the results of a multicentre, randomised, double-bli nd, parallel-group study comparing the efficacy, and safety of cerivastatin 0.4 mg/day and cerivastatin 0.2 mg/day in patients with primary hyperchole sterolaemia. Exploratory analysis in this study suggested a gender differen ce ill the 0.4 wry group: mean low-density lipoprotein cholesterol (LDL-C) decreased by 44.4 +/- 8.9% in women, compared with a mean decrease of 37.0 +/- 0.9% in men (p < 0.046). This paper reports the results of further sub- analyses from this study. Overall in the per-protocol (PP) population. 71.5 % (n = 73) of women taking cerivastatin 0.4 mg had all LDL-C decrease of > 40%, compared with 38.0% (n = 76) of men taking the same dose. In the ceriv astatin 0.2 mg PP population, 34% (n = 17) of women had an LDL-C decrease o f > 40%, compared with 19% (n = Ig) of men. Mean LDL-C/HDL-C ratio decrease d by 43% from baseline to the end of the study in the cerivastatin 0.4 mg P P group: -41.3% in males la. -48.3% in females. In the cerivastatin 0.2 mg group, the decrease in LDL-C/HDL-C ratio from baseline to endpoint did not markedly differ between genders: -37.0% for males vs. -37.3% for females. C ategorial analysis of the LDL-C/HDL-C ratio found that 90% of PP patients t aking cerivastatin 0.4 mg, and 84% of PP patients taking cerivastatin 0.2 m y, had a low CHD risk (defined as a LDL-C/HDL-C ratio less than or equal to 3) after 8 weeks of treatment. The 6th and 95th percentiles of the distrib ution of LDL-C reduction from baseline revealed that 90% of PP patients tak ing cerivastatin 0.4 mg had all LDL-C reduction of between 22% and 56%. The mean LDL-C reduction for this 90% subset of patients uas 40.1%. The same a nalysis for PP patients taking cerivastatin 0.2 my found that 90% had all L DL-C reduction of between 13% and 49%. The mean LDL-C reduction in this 90% subset of patients was 31.5%. Of the patients raking cerivastatin 0.4 mg a nd valid for treatment according to National Cholesterol( Education Program (NCEP) criteria, 71% (149/211) achieved NCEP targets for LDL-C at Week 16.